Kyverna Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Kyverna Therapeutics

21/03/2025 20:13

Kyverna Therapeutics Inc KYTX.OQ KYTX.O is expected to show no change in quarterly revenue when it reports  results on March 24 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Kyverna Therapeutics Inc is for a loss of 84 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Kyverna Therapeutics Inc is $18.50​, above​ its last closing price of $2.27. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.79
-0.79
-0.80
Missed
-1.5
Jun. 30 2024
-0.69
-0.70
-0.67
Beat
4
Mar. 31 2024
-0.96
-0.84
-1.12
Missed
-33.3​
Dec. 31 2023
-3.23
-3.23
-26.86
Missed
-732.4
​​
​

This summary was machine generated March 21 at 20:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)